Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Robinson KA, Odelola OA, Saldanha IJ.

Cochrane Database Syst Rev. 2016 Jul 20;7:CD007743. doi: 10.1002/14651858.CD007743.pub6. Review.

PMID:
27439110
2.

Limited Evidence on the Management of Respiratory Tract Infections in Down's Syndrome: A Systematic Review.

Manikam L, Reed K, Venekamp RP, Hayward A, Littlejohns P, Schilder A, Lakhanpaul M.

Pediatr Infect Dis J. 2016 Oct;35(10):1075-9. doi: 10.1097/INF.0000000000001243.

3.

Best practice in the prevention and management of paediatric respiratory syncytial virus infection.

Drysdale SB, Green CA, Sande CJ.

Ther Adv Infect Dis. 2016 Apr;3(2):63-71. doi: 10.1177/2049936116630243. Review.

4.

Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review.

French CE, McKenzie BC, Coope C, Rajanaidu S, Paranthaman K, Pebody R, Nguyen-Van-Tam JS; Noso-RSV Study Group., Higgins JP, Beck CR.

Influenza Other Respir Viruses. 2016 Jul;10(4):268-90. doi: 10.1111/irv.12379. Review.

5.

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective.

Homaira N, Rawlinson W, Snelling TL, Jaffe A.

Int J Pediatr. 2014;2014:571609. doi: 10.1155/2014/571609. Review.

6.

[Update of recommendations on the use of palivizumab as prophylaxis in RSV infections].

Figueras Aloy J, Carbonell Estrany X; Comité de Estándares de la SENeo..

An Pediatr (Barc). 2015 Mar;82(3):199.e1-2. doi: 10.1016/j.anpedi.2014.10.004. Spanish.

7.

Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants.

Baraldi E, Lanari M, Manzoni P, Rossi GA, Vandini S, Rimini A, Romagnoli C, Colonna P, Biondi A, Biban P, Chiamenti G, Bernardini R, Picca M, Cappa M, Magazzù G, Catassi C, Urbino AF, Memo L, Donzelli G, Minetti C, Paravati F, Di Mauro G, Festini F, Esposito S, Corsello G.

Ital J Pediatr. 2014 Oct 24;40:65. doi: 10.1186/1824-7288-40-65.

8.

Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.

Wegzyn C, Toh LK, Notario G, Biguenet S, Unnebrink K, Park C, Makari D, Norton M.

Infect Dis Ther. 2014 Dec;3(2):133-58. doi: 10.1007/s40121-014-0046-6. Review.

9.

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.

American Academy of Pediatrics Committee on Infectious Diseases.; American Academy of Pediatrics Bronchiolitis Guidelines Committee..

Pediatrics. 2014 Aug;134(2):415-20. doi: 10.1542/peds.2014-1665. Erratum in: Pediatrics. 2014 Dec;134(6):1221.

10.

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.

American Academy of Pediatrics Committee on Infectious Diseases.; American Academy of Pediatrics Bronchiolitis Guidelines Committee..

Pediatrics. 2014 Aug;134(2):e620-38. doi: 10.1542/peds.2014-1666.

11.

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Robinson KA, Odelola OA, Saldanha IJ.

Cochrane Database Syst Rev. 2014 May 22;(5):CD007743. doi: 10.1002/14651858.CD007743.pub5. Review. Update in: Cochrane Database Syst Rev. 2016;7:CD007743.

PMID:
24851825
12.

Is palivizumab effective as a prophylaxis of respiratory syncytial virus infections in cystic fibrosis patients? A meta-analysis.

Sánchez-Solis M, Gartner S, Bosch-Gimenez V, Garcia-Marcos L.

Allergol Immunopathol (Madr). 2015 May-Jun;43(3):298-303. doi: 10.1016/j.aller.2013.09.003. Review.

PMID:
24231153
13.

Use of palivizumab in infants and young children with severe respiratory disease: a Delphi study.

Gaboli M, de la Cruz ÒA, de Agüero MI, Moreno-Galdó A, Pérez GP, de Querol MS.

Pediatr Pulmonol. 2014 May;49(5):490-502. doi: 10.1002/ppul.22826.

PMID:
23775884
14.

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Robinson KA, Odelola OA, Saldanha IJ, McKoy NA.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD007743. doi: 10.1002/14651858.CD007743.pub4. Review. Update in: Cochrane Database Syst Rev. 2014;(5):CD007743.

PMID:
23737087
15.

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.

Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD006602. doi: 10.1002/14651858.CD006602.pub4. Review.

PMID:
23633336
16.

Effects of parental and household smoking on the risk of respiratory syncytial virus (RSV) hospitalisation in late-preterm infants and the potential impact of RSV prophylaxis.

Carbonell-Estrany X, Fullarton JR, Gooch KL, Vo PG, Figueras-Aloy J, Lanari M, Gouyon JB, Liese JG.

J Matern Fetal Neonatal Med. 2013 Jun;26(9):926-31. doi: 10.3109/14767058.2013.765850.

PMID:
23379728
17.

A review of cost-effectiveness of palivizumab for respiratory syncytial virus.

Hussman JM, Li A, Paes B, Lanctôt KL.

Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):553-67. doi: 10.1586/erp.12.45. Review.

PMID:
23140255
18.

The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence.

Hussman JM, Lanctôt KL, Paes B.

J Med Econ. 2013;16(1):115-24. doi: 10.3111/13696998.2012.734886. Review.

PMID:
23016567
19.

Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.

Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK.

Antimicrob Agents Chemother. 2012 Sep;56(9):4927-36. doi: 10.1128/AAC.06446-11. Erratum in: Antimicrob Agents Chemother. 2012 Oct;56(10):5431.

20.

Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients.

Hynicka LM, Ensor CR.

Ann Pharmacother. 2012 Apr;46(4):558-66. doi: 10.1345/aph.1Q553. Review.

PMID:
22395247
Items per page

Supplemental Content

Loading ...
Support Center